Transcarent, Inc. entered a merger agreement on January 8, 2025, to acquire Accolade, Inc. (ACCD) in an all-cash deal worth $621 million.
Under the agreement, Transcarent will acquire Accolade for $7.03 per share in cash, representing a premium of 109.85% from the stock’s last close.
Accolade is a Personalized Healthcare company that provides technology-enabled solutions to help individuals and their families navigate healthcare and benefits, offering virtual primary care, mental health support, expert medical opinions, and care navigation to improve outcomes and reduce costs.
Transcarent is a healthcare experience company that simplifies access to high-quality, affordable care through an AI-powered platform, offering services like WayFinding, virtual care, and personalized clinical guidance.
The deal will combine Transcarent’s AI-powered WayFinding and care programs—like Cancer Care, Surgery Care, Weight Health, and Pharmacy Benefits—with Accolade’s Personalized Healthcare Platform, which includes services like advocacy, expert medical opinions, and primary care.
Transcarent will fund the deal with fully secured equity financing, led by General Catalyst and Glen Tullman’s 62 Ventures.
Once the acquisition is completed, expected in the second quarter of 2025, Accolade will become a privately owned company.
Transcarent is acquiring Accolade at 1.21 times its sales.
To get a more comprehensive understanding of this merger and acquisition transaction, please refer to the Deal Metrics page here:
Deal Metrics for the acquisition of Accolade, Inc. (ACCD) by Transcarent, Inc.
The in-depth Deal Metrics page for each merger or acquisition includes:
Disclaimer: Please carry out your own due diligence prior to buying or selling any securities mentioned in this article. We do not guarantee the completeness or accuracy of the content or data provided in this article.
Editor’s Note: Baranjot Kaur contributed to this article